Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
According to Apollo Endosurgery, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.43. At the end of 2021 the company had a P/B ratio of 4.16.
Year | P/B ratio |
---|---|
2022 | 12.43 |
2021 | 4.16 |
2020 | 11.46 |
2019 | 28.92 |
2018 | 2.37 |
2017 | 1.52 |
2016 | 0.11 |
2015 | 0.55 |
2014 | 2.95 |
2013 | 5.74 |
2012 | 3.63 |
2011 | 119.13 |
2010 | 16.50 |
2009 | 23.10 |
2008 | 14.14 |
2007 | 14.20 |
2006 | 10.20 |
2005 | 1.27 |